<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19632" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Clostridioides difficile infection</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mada</surname>
            <given-names>Pradeep Kumar</given-names>
          </name>
          <aff>Louisiana State University Shreveport</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Alam</surname>
            <given-names>Mohammed U.</given-names>
          </name>
          <aff>Louisiana State University HSC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pradeep Kumar Mada declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohammed Alam declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>4</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19632.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p><italic toggle="yes">Clostridioides difficile</italic>, formerly known as <italic toggle="yes">Clostridium difficile</italic>, is a gram-positive and spore-forming bacterium. This obligate anaerobic bacillus is recognized for its ability to produce toxins and cause diarrhea, which is often associated with antibiotic usage.&#x000a0;Although traditionally considered a primary healthcare-associated infection,&#x000a0;<italic toggle="yes">C difficile</italic> is also increasingly diagnosed within community settings.&#x000a0;The emergence of the newer, hypervirulent, antibiotic-resistant, epidemic strain&#x02014;ribotype 027, also known as the North American pulsed-field gel electrophoresis type 1 (or NAP1) strain&#x02014;has resulted in increased frequency and severity of infections over the last 2 decades.&#x000a0;<italic toggle="yes">C difficile</italic> infection ranges from asymptomatic carriage to severe conditions such as pseudomembranous colitis and toxic megacolon, which can lead to fatal outcomes. As a primary cause of healthcare-associated colitis, this bacterium presents a significant public health challenge due to its transmissibility and associated morbidity and mortality.&#x000a0;</p>
        <p>Diagnosis relies on clinical presentation and is confirmed through stool testing.&#x000a0;Treatment involves implementing infection control measures, discontinuing the causative antibiotics, and administering appropriate medication based on evidence-based guidelines. However, testing and treatment are not recommended for asymptomatic individuals.&#x000a0;Early recognition and management are crucial in controlling the spread of the infection and mitigating the impact of <italic toggle="yes">C difficile</italic> infection.&#x000a0;This activity examines the etiology, presentation, evaluation, and management of infections caused by the&#x000a0;<italic toggle="yes">C difficile</italic>&#x000a0;bacterium. This activity also highlights the interprofessional healthcare team's roles in assessing, diagnosing, and treating infections caused by <italic toggle="yes">C difficile</italic>.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify risk factors associated with <italic toggle="yes">Clostridioides difficile</italic> infections in patients, such as recent antibiotic use, hospitalization, and previous <italic toggle="yes">C difficile</italic> history.</p></list-item><list-item><p>Screen patients with diarrhea for <italic toggle="yes">Clostridioides</italic><italic toggle="yes">&#x000a0;difficile</italic>&#x000a0;infections using appropriate diagnostic tests, considering their symptoms, signs, recent healthcare exposure, and antibiotic use.</p></list-item><list-item><p>Apply appropriate treatment modalities for <italic toggle="yes">Clostridioides</italic><italic toggle="yes">&#x000a0;difficile</italic>&#x000a0;infections, including antimicrobial therapy, fecal microbiota transplantation, and surgical intervention when indicated.</p></list-item><list-item><p>Collaborate with other healthcare professionals to optimize <italic toggle="yes">Clostridioides</italic><italic toggle="yes">&#x000a0;difficile</italic>&#x000a0;infections and coordinate care for patients&#x000a0;across different healthcare settings to ensure continuity and prevent recurrence.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19632&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19632">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19632.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p><italic toggle="yes">Clostridioides difficile, </italic>formerly<italic toggle="yes"> Clostridium difficile,</italic>&#x000a0;is a gram-positive and spore-forming bacterium. This obligate anaerobic bacillus is recognized for its ability to produce toxins and is the leading cause of antibiotic-associated diarrhea worldwide. <italic toggle="yes">C difficile</italic>&#x000a0;infections can range from an asymptomatic carrier to diarrhea, progressing to severe conditions such as pseudomembranous colitis and toxic megacolon with septic shock, often resulting in a high mortality rate. Although&#x000a0;traditionally considered a primary healthcare-associated infection, an&#x000a0;increasing incidence of community-acquired<italic toggle="yes">&#x000a0;C difficile</italic> infections also exists.<xref ref-type="bibr" rid="article-19632.r1">[1]</xref>&#x000a0;The emergence of a newer hypervirulent strain, the North American pulsed-field gel electrophoresis type 1 (NAP1), has been attributed to increased incidence and severity of <italic toggle="yes">C difficile</italic> infections over the last 2 decades.<xref ref-type="bibr" rid="article-19632.r2">[2]</xref><xref ref-type="bibr" rid="article-19632.r3">[3]</xref></p>
        <p><italic toggle="yes">C difficile</italic> can colonize the intestines of healthy people without causing infection and survive on surfaces in the hospital and soil for extended periods. Contaminated surfaces and medical equipment in healthcare facilities&#x000a0;can become reservoirs&#x000a0;for <italic toggle="yes">C difficile</italic> spores, potentially transmitting to patients if proper cleaning protocols are not routinely implemented.<xref ref-type="bibr" rid="article-19632.r4">[4]</xref> The most significant risk factor for <italic toggle="yes">C difficile</italic> infection is broad-spectrum antibiotics.<xref ref-type="bibr" rid="article-19632.r5">[5]</xref><xref ref-type="bibr" rid="article-19632.r6">[6]</xref> Patients can be colonized with <italic toggle="yes">C difficile</italic> without symptoms, but antibiotic use disturbs the balance of gut flora, enabling<italic toggle="yes"> C difficile </italic>overgrowth and infection. Additional risk factors for<italic toggle="yes"> C difficile</italic> infection include proton pump inhibitors, advanced age, immunosuppression, underlying health conditions, prior<italic toggle="yes"> C difficile</italic> infection, recent hospitalization, prolonged hospital stays, inadequate infection control, and suboptimal antibiotic stewardship in healthcare settings, facilitating<italic toggle="yes"> C difficile</italic> transmission among patients.<xref ref-type="bibr" rid="article-19632.r7">[7]</xref><xref ref-type="bibr" rid="article-19632.r8">[8]</xref></p>
        <p>While <italic toggle="yes">C difficile</italic> infection is primarily associated with healthcare settings, a growing recognition of community-acquired cases exists, particularly among younger and healthier individuals with minimal recent healthcare exposure. The emergence of&#x000a0;genome sequencing has revealed that reservoirs for&#x000a0;<italic toggle="yes">C difficile</italic>&#x000a0;exist within healthcare systems, environment, food, soil, and animals,&#x000a0;comprising a "One Health" continuum.<xref ref-type="bibr" rid="article-19632.r9">[9]</xref>&#x000a0;Managing<italic toggle="yes"> C difficile</italic> infections remains challenging due to its increasing global burden,&#x000a0;emergence&#x000a0;in community settings, complexities in handling severe and recurrent cases, and rising morbidity and mortality rates. Understanding the epidemiology of <italic toggle="yes">C difficile</italic> infection is crucial for implementing effective prevention and control measures in healthcare settings and the community. These strategies include prudent antibiotic use, hand hygiene practices, environmental cleaning, and early detection and management of cases.<xref ref-type="bibr" rid="article-19632.r4">[4]</xref>&#x000a0; &#x000a0; &#x000a0;</p>
      </sec>
      <sec id="article-19632.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p><italic toggle="yes">C difficile&#x000a0;</italic>is a gram-positive, anaerobic, spore-forming, and toxin-producing bacterium, which is also a significant cause of antibiotic-associated&#x000a0;colitis worldwide (see <bold>Image.</bold> Micrograph of <italic toggle="yes">Clostridioides</italic><italic toggle="yes">&#x000a0;difficile</italic> Showing Colitis). <italic toggle="yes">C difficile</italic>&#x000a0;infection ranks&#x000a0;among the most prevalent healthcare-associated infections, easily transmitted between patients and originating from healthcare and community reservoirs. Clinical symptoms vary from asymptomatic carriage to mild diarrhea to severe conditions such as pseudomembranous colitis and toxic megacolon with septic shock. The potential of <italic toggle="yes">C difficile&#x000a0;</italic>to cause healthcare-associated outbreaks, along with high morbidity and recurrent infections, poses treatment challenges, associated costs, and, in severe cases, mortality.<xref ref-type="bibr" rid="article-19632.r10">[10]</xref></p>
        <p>The most significant risk factor for&#x000a0;<italic toggle="yes">C difficile</italic>&#x000a0;infection is antibiotic use, particularly broad-spectrum antibiotics. Various antibiotic classes, including penicillins, cephalosporins, fluoroquinolones, and clindamycin, have been associated with the development of the disease.<xref ref-type="bibr" rid="article-19632.r5">[5]</xref><xref ref-type="bibr" rid="article-19632.r6">[6]</xref> Advancements in our comprehension of the gut microbiome's role contribute to a deeper understanding of the disease's pathophysiology.&#x000a0;Patients may carry&#x000a0;<italic toggle="yes">C difficile</italic>&#x000a0;without symptoms, and antibiotic use can disturb the balance of the gut microbiome, leading to dysbiosis and enabling <italic toggle="yes">C difficile</italic> proliferation and infection.<xref ref-type="bibr" rid="article-19632.r11">[11]</xref>&#x000a0;Other risk factors for developing&#x000a0;<italic toggle="yes">C difficile</italic>&#x000a0;infection include proton pump inhibitors, advanced age, immunosuppression, underlying comorbidities, previous&#x000a0;<italic toggle="yes">C difficile</italic>&#x000a0;infection,&#x000a0;kidney and hepatic failure, recent hospitalization, and prolonged hospital stays.<xref ref-type="bibr" rid="article-19632.r7">[7]</xref><xref ref-type="bibr" rid="article-19632.r8">[8]</xref>&#x000a0;Incomplete&#x000a0;infection control and antibiotic stewardship practices in healthcare institutions allow&#x000a0;<italic toggle="yes">C difficile</italic>&#x000a0;transmission among patients.</p>
        <p><italic toggle="yes">C difficile</italic> produces 2 types of toxins&#x02014;A and B&#x02014;which are virulent factors in its pathogenicity. Most pathogenic strains associated with <italic toggle="yes">C difficile</italic> infection produce toxins A and B. However, globally, there are reports of strains producing only toxin B.<xref ref-type="bibr" rid="article-19632.r12">[12]</xref>&#x000a0;In 2005,&#x000a0;due to&#x000a0;the increasing incidence and virulence of<italic toggle="yes">&#x000a0;C&#x000a0;</italic><italic toggle="yes">difficile&#x02013;</italic>associated&#x000a0;diseas<italic toggle="yes">e</italic>, a newer strain was identified that contained a binary toxin (referred to as binary toxin CDT) in addition to toxins A and B. Deletions in the gene <italic toggle="yes">tcd</italic>, which serves as a negative regulator of toxins A and B, have been identified, potentially leading to overproduction of these virulence factors.&#x000a0;The emergence of the newer, hypervirulent, antibiotic-resistant, epidemic strain&#x02014;ribotype 027, commonly known as NAP1/B1/027 or the North American pulsed-field gel electrophoresis type 1 strain, restriction endonuclease analysis type B1, or polymerase chain reaction ribotype 027&#x02014;is characterized by increased production of toxins A and B, as well as the&#x000a0;production of a binary toxin CDT, and fluoroquinolone resistance.<xref ref-type="bibr" rid="article-19632.r11">[11]</xref></p>
      </sec>
      <sec id="article-19632.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p><italic toggle="yes"><italic toggle="yes">C difficile</italic>&#x000a0;i</italic>s the&#x000a0;primary causative agent of&#x000a0;healthcare-associated post-antibiotic colitis, posing a significant public health challenge due to its transmissibility and associated morbidity and mortality.<xref ref-type="bibr" rid="article-19632.r13">[13]</xref>
<italic toggle="yes">C difficile</italic>&#x000a0;is ubiquitous and can colonize the intestines of up to 3% to 5% of healthy individuals without causing any infections.<xref ref-type="bibr" rid="article-19632.r14">[14]</xref>&#x000a0;Although transmission of <italic toggle="yes">C difficile&#x000a0;</italic>primarily occurs fecal-orally, it can also stem from various other environmental sources, such as soil. However, the bacterium is&#x000a0;more commonly transmitted via contaminated surfaces in hospitals, often in the form of spores.&#x000a0;Contaminated surfaces and medical equipment in healthcare facilities&#x000a0;can become reservoirs&#x000a0;for&#x000a0;<italic toggle="yes">C difficile&#x000a0;</italic>spores,&#x000a0;potentially transmitting to patients if proper infection prevention and control practices, including appropriate cleaning protocols, are not enforced.<xref ref-type="bibr" rid="article-19632.r4">[4]</xref>&#x000a0;The healthcare environment presents a conducive setting for <italic toggle="yes">C difficile</italic> transmission, owing to the challenge of eradicating spores and the prevalent use of antimicrobials, which fosters the development of <italic toggle="yes">C difficile</italic> infections.</p>
        <p><italic toggle="yes">C difficile</italic> infection has primarily been associated with healthcare settings. However, recent reports indicate a surge in <italic toggle="yes">C difficile</italic> infections in the community among individuals with no healthcare system affiliation or exposure to antibiotics.<xref ref-type="bibr" rid="article-19632.r15">[15]</xref><xref ref-type="bibr" rid="article-19632.r16">[16]</xref>&#x000a0;Consequently, concerted efforts have been directed toward reducing the incidence of <italic toggle="yes">C difficile</italic> to enhance patient safety. This involves enhancing detection, surveillance, and infection prevention and control practices to mitigate the estimated burden of&#x000a0;<italic toggle="yes">C difficile</italic>.&#x000a0;Antibiotic misuse significantly heightens the risk of <italic toggle="yes">C difficile</italic> infections, with over half of hospitalized patients receiving antibiotics during their stay and 30% to 50% of prescribed antibiotics being unnecessary or incorrect.<xref ref-type="bibr" rid="article-19632.r17">[17]</xref>&#x000a0;</p>
        <p>The last 2 decades have been crucial in enhancing the detection, surveillance, and estimation of the burden of <italic toggle="yes">C difficile</italic> infections globally, including in the United States and Europe. Countries have made concerted efforts to implement diagnostic, surveillance, and infection prevention and control protocols and tools, particularly in hospital settings. However, considering differences in practices and&#x000a0;disparities in financial and staff resources across different regions is essential, which may influence the accuracy of estimated data concerning the burden of <italic toggle="yes">C&#x000a0;difficile</italic>&#x000a0;infections.<xref ref-type="bibr" rid="article-19632.r18">[18]</xref>&#x000a0; Reviewing data from&#x000a0;the early 2000s, a notable increase was seen in the&#x000a0;incidence of&#x000a0;<italic toggle="yes">C difficile</italic> infections and&#x000a0;related hospitalizations, attributed to the emergence of the epidemic strain<italic toggle="yes">&#x000a0;C difficile</italic> NAP1/B1/027.<xref ref-type="bibr" rid="article-19632.r19">[19]</xref>&#x000a0;In a 2007 study by Hall et al, a&#x000a0;<italic toggle="yes">C difficile</italic>&#x000a0;infection emerged as the leading cause of gastroenteritis, correlating with a 5-fold increase in mortality.<xref ref-type="bibr" rid="article-19632.r20">[20]</xref>&#x000a0;In addition, Dubberke et al estimated that in acute-care facilities in the United States, <italic toggle="yes">C difficile</italic>&#x000a0;infections may have been responsible for&#x000a0;$4.8 billion in excess costs.<xref ref-type="bibr" rid="article-19632.r21">[21]</xref></p>
        <p>Furthermore, data from a 2011 article published by the&#x000a0;Centers for Disease Control and Prevention and authored by Lessa et al&#x000a0;demonstrated a rise in&#x000a0;<italic toggle="yes">C difficile</italic> incidence across 10 geographic areas in the United States compared to the previous decade, with a higher occurrence observed among females and individuals aged 65 and older.<xref ref-type="bibr" rid="article-19632.r22">[22]</xref>&#x000a0;This increase&#x000a0;may have been associated with adopting newer, more sensitive <italic toggle="yes">C difficile</italic> assays, such as nucleic acid amplification tests (NAATs).<xref ref-type="bibr" rid="article-19632.r22">[22]</xref>&#x000a0;The data indicated that approximately half a million Americans are infected by <italic toggle="yes">C difficile</italic> infections annually. Among those infected, about 29,000 patients experienced fatal outcomes within a month of diagnosis, and 15,000 of these deaths were directly linked to <italic toggle="yes">C difficile</italic> infection. Moreover, approximately 83,000 patients experienced at least a recurrence of <italic toggle="yes">C difficile</italic> infection, and 29,000 of them succumbed within 30 days of the initial diagnosis.<xref ref-type="bibr" rid="article-19632.r22">[22]</xref>&#x000a0;However, more recent data from the United States&#x000a0;<xref ref-type="bibr" rid="article-19632.r1">[1]</xref><xref ref-type="bibr" rid="article-19632.r23">[23]</xref><xref ref-type="bibr" rid="article-19632.r19">[19]</xref>&#x000a0;and Europe&#x000a0;<xref ref-type="bibr" rid="article-19632.r24">[24]</xref> show a decreasing prevalence and trend&#x000a0;of <italic toggle="yes">C difficile</italic>&#x000a0;infections within healthcare systems, particularly notable in the prevalence of NAP1/B1/027 strain. This decrease may be attributed to a multifaceted approach to reduce unnecessary antimicrobial usage, implement antibiotic stewardship practices, and enhance infection control procedures. Nevertheless, heterogeneity in testing, surveillance, infection prevention, and control practices prevails among hospitals globally and between countries.<xref ref-type="bibr" rid="article-19632.r25">[25]</xref></p>
      </sec>
      <sec id="article-19632.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The human gastrointestinal tract harbors a diverse array of bacteria, collectively forming a microbial community known as the microbiome, comprising approximately 100 trillion microorganisms.<xref ref-type="bibr" rid="article-19632.r26">[26]</xref>&#x000a0;This microbiome is vital for maintaining homeostasis and serves various functions, such as food fermentation, acting as a barrier against pathogens, synthesizing vitamins, and regulating metabolism and immunity.<xref ref-type="bibr" rid="article-19632.r26">[26]</xref> Reductions in both the diversity and abundance of these bacteria and perturbations in the composition of the microbiome can disrupt interactions with the host and the immune system. In the case of <italic toggle="yes">C difficile</italic>, such disruptions can facilitate its colonization of the human gut, even in healthy individuals. The link between antibiotics and the onset of <italic toggle="yes">C difficile</italic> infections stems from the dysbiosis within the gut microbiome ecosystem induced by antibiotic use.<xref ref-type="bibr" rid="article-19632.r27">[27]</xref>&#x000a0;The most significant risk factor for developing&#x000a0;<italic toggle="yes">C difficile</italic>&#x000a0;infection is the use of antibiotics, particularly broad-spectrum antibiotics. Several classes of antibiotics,&#x000a0;including penicillins, cephalosporins, fluoroquinolones, and clindamycin, are associated with the onset of the disease, although any antibiotic use can potentially lead to<italic toggle="yes">&#x000a0;C difficile</italic>&#x000a0;infections.<xref ref-type="bibr" rid="article-19632.r5">[5]</xref><xref ref-type="bibr" rid="article-19632.r6">[6]</xref>&#x000a0;Our understanding of the role of the gut microbiome facilitates a better understanding of the pathophysiology of the disease.&#x000a0;</p>
        <p><italic toggle="yes"><italic toggle="yes">C difficile&#x000a0;</italic></italic>is ubiquitous and can colonize the intestines of up to 3% to 5% of healthy individuals without causing infections.<xref ref-type="bibr" rid="article-19632.r14">[14]</xref>&#x000a0;Even healthy adults with adequate immune responses can become asymptomatic carriers of the <italic toggle="yes">C difficile</italic>. Neonates, lacking intestinal receptors for <italic toggle="yes">C difficile</italic>, exhibit a high asymptomatic carrier rate.<xref ref-type="bibr" rid="article-19632.r28">[28]</xref>&#x000a0;Antibiotics alter the microbial balance in the large intestine, increasing susceptibility to <italic toggle="yes">C difficile</italic> infection, which is transmitted through the fecal-oral route. Diarrhea and pseudomembranous colitis, characteristic symptoms of <italic toggle="yes">C difficile</italic> infection, result from clostridial glycosylation exotoxins&#x02014;toxin A (TcdA), an enterotoxin, and toxin B (TcdB), which is cytotoxic.<xref ref-type="bibr" rid="article-19632.r29">[29]</xref>&#x000a0;Toxin A has a carbohydrate receptor binding site that facilitates the intracellular transport of toxins A and B.<xref ref-type="bibr" rid="article-19632.r30">[30]</xref> After becoming intracellular, both toxins cause the inactivation of pathways mediated by the Rho family of proteins, resulting in damage to colonocytes, disruption of intercellular tight junctions, and colitis.<xref ref-type="bibr" rid="article-19632.r31">[31]</xref> Furthermore, toxin A directly activates neutrophils, while toxins A and B contribute to neutrophil chemotaxis.<xref ref-type="bibr" rid="article-19632.r32">[32]</xref>&#x000a0;A newer strain was identified in 2005, featuring a binary toxin CDT alongside toxins A and B. Additionally, deletions in the gene <italic toggle="yes">tcd</italic>, acting as a negative regulator of toxins A and B, were identified, potentially leading to an overproduction of these virulence factors. This new epidemic strain&#x02014;ribotype 027, commonly known as NAP1/B1/027 or North American pulsed-field gel electrophoresis type 1, restriction endonuclease analysis type B1, or polymerase chain reaction ribotype 027&#x02014;is characterized by increased production of toxins A and B,&#x000a0;as well as binary toxin CDT, and demonstrates resistance to fluoroquinolones.<xref ref-type="bibr" rid="article-19632.r11">[11]</xref></p>
      </sec>
      <sec id="article-19632.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Clinical presentations of <italic toggle="yes">C difficile</italic>&#x000a0;infections vary from being asymptomatic carriers to symptomatic patients experiencing mild diarrhea to severe manifestations such as fever, abdominal pain, pseudomembranous colitis, toxic megacolon, and septic shock. The severity of clinical signs and symptoms varies depending on factors such as the patient's overall health status and the specific strain of <italic toggle="yes">C difficile</italic>&#x000a0;involved. Common symptoms associated with diarrhea and colitis caused by <italic toggle="yes">C difficile</italic> include watery diarrhea with mucus or occult blood, anorexia, nausea, vomiting, low-grade fever, and lower abdominal pain.<xref ref-type="bibr" rid="article-19632.r33">[33]</xref>&#x000a0;In some cases, patients may progress to fulminant colitis, characterized by diarrhea, diffuse abdominal pain, abdominal distension, hypovolemia, toxic megacolon, and perforated bowel&#x000a0;with peritonitis.<xref ref-type="bibr" rid="article-19632.r34">[34]</xref>&#x000a0;Other manifestations of the disease include protein-losing enteropathy and extra-colonic symptoms such as appendicitis and reactive arthritis.<xref ref-type="bibr" rid="article-19632.r35">[35]</xref><xref ref-type="bibr" rid="article-19632.r36">[36]</xref>&#x000a0;Recurrent infections caused by <italic toggle="yes">C difficile&#x000a0;</italic>are defined by the complete resolution of symptoms after treatment, followed by a recurrence.<xref ref-type="bibr" rid="article-19632.r37">[37]</xref>&#x000a0;Risk factors for recurrence include recent hospitalization, antibiotic use, or close contact with individuals who have experienced diarrhea.</p>
      </sec>
      <sec id="article-19632.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p><italic toggle="yes">C difficile</italic> should be considered in patients with 3 or more loose stools within 24 hours, particularly those with a recent history of hospitalization and antibiotic use within the last 3 months.&#x000a0;Additionally, diarrhea persisting for 48 hours after hospital admission warrants consideration. Evaluating for community-acquired cases is important, even in patients without a history of such exposures (see <bold>Image.</bold>
<italic toggle="yes">Clostridioides</italic>&#x000a0;<italic toggle="yes">difficile</italic> Pathology and Diagnosis). Diagnostic tests for <italic toggle="yes">C difficile</italic>&#x000a0;infections include an enzyme immunoassay for glutamate dehydrogenase, toxigenic cultures, cell culture cytotoxicity neutralization tests, toxins A and B enzyme immunoassays (EIAs), and NAATs. A singular test lacks sufficient informativeness, thus necessitating a 2-step, sequential testing approach.<xref ref-type="bibr" rid="article-19632.r38">[38]</xref>&#x000a0;In&#x000a0;the diagnostic process, the primary focus is detecting the presence of <italic toggle="yes">C difficile</italic> antigen, achieved through either GDH testing for glutamate dehydrogenase produced by <italic toggle="yes">C difficile</italic> or NAATs. Negative results from these tests typically conclude the testing process. However, if positive, they do not indicate toxin presence. Therefore, EIAs should be used subsequently to detect and confirm toxin production&#x000a0;(see <bold>Image.</bold> Impression Smear of <italic toggle="yes">Clostridioides difficile</italic>).</p>
        <p>Most guidelines recommend a 2-step method for diagnosing <italic toggle="yes">C difficile</italic>&#x000a0;infections, although using a NAAT alone or in conjunction with GDH in a 2-step process is also feasible. While selective anaerobic culture is an option for diagnosis, it is time-consuming (see&#x000a0;<bold>Image.</bold>&#x000a0;<italic toggle="yes">Clostridioides</italic>&#x000a0;<italic toggle="yes">difficile</italic>&#x000a0;Cultures on&#x000a0;Cycloserine Mannitol Agar).<xref ref-type="bibr" rid="article-19632.r39">[39]</xref><xref ref-type="bibr" rid="article-19632.r40">[40]</xref><xref ref-type="bibr" rid="article-19632.r38">[38]</xref>&#x000a0;Studies&#x000a0;have demonstrated that PCR-based diagnostic approaches, whether single or multistep, offer the highest sensitivity and specificity for diagnosing<italic toggle="yes">&#x000a0;C difficile</italic>.<xref ref-type="bibr" rid="article-19632.r33">[33]</xref>&#x000a0;In certain scenarios, additional diagnostic modalities, such as radiographic imaging of the abdomen and pelvis or lower gastrointestinal endoscopy, may be warranted, particularly when patients present with fulminant colitis or alternative diagnoses are under consideration.<xref ref-type="bibr" rid="article-19632.r40">[40]</xref></p>
      </sec>
      <sec id="article-19632.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Managing <italic toggle="yes">C difficile</italic> infections involves a multistep approach, including implementing infection prevention and control protocols for suspected or confirmed cases, making a definite diagnosis, discontinuing unnecessary antibiotics if possible, and administering appropriate medication following evidence-based guidelines. Testing for <italic toggle="yes">C difficile</italic> infection is unnecessary in asymptomatic patients who do not have diarrhea, and asymptomatic individuals with positive stool toxin tests do not require treatment&#x000a0;(see <bold>Image</bold>. Course of <italic toggle="yes">Clostridioides&#x000a0;difficile</italic>&#x000a0;Infections). Response to treatment is defined as the resolution of diarrhea or the presence of formed stool for at least 48 hours after completing treatment. Refractory <italic toggle="yes">C difficile</italic> infections occur when there is no response to treatment after a specified duration. Recurrence refers to a new episode within 8 weeks following the complete resolution of a previous <italic toggle="yes">C difficile</italic> infection.<xref ref-type="bibr" rid="article-19632.r41">[41]</xref>&#x000a0;Severe <italic toggle="yes">C difficile</italic> infection is characterized by a white blood cell count exceeding 15,000 cells/&#x003bc;L, serum albumin below 3 g/dL, and serum creatinine elevated to more than 1.5 times the premorbid level.&#x000a0;</p>
        <p>Multiple recommendations and guidelines from different societies provide therapeutic guidance for <italic toggle="yes">C difficile</italic> infections, with minor variations. The fundamental approach to treatment is generally consistent.<xref ref-type="bibr" rid="article-19632.r42">[42]</xref><xref ref-type="bibr" rid="article-19632.r41">[41]</xref><xref ref-type="bibr" rid="article-19632.r43">[43]</xref>&#x000a0;Previously, 3 antibiotics&#x02014;oral vancomycin, oral or intravenous metronidazole, and oral fidaxomicin&#x02014;were commonly used to treat <italic toggle="yes">C difficile</italic>&#x000a0;infections.</p>
        <list list-type="bullet">
          <list-item>
            <p>Vancomycin and fidaxomicin&#x000a0;are now considered standard-of-care (SoC) antibiotics for <italic toggle="yes">C difficile</italic>&#x000a0;infections, with specific treatment recommendations tailored to first episodes, recurrences, or severe infections.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Metronidazole is no longer recommended as first-line therapy for <italic toggle="yes">C difficile</italic> infections and should only be considered in cases where vancomycin or fidaxomicin are unavailable. Alternatively, intravenous metronidazole may be necessary if ileus is present, as oral vancomycin inadequately secretes into the colon.</p>
          </list-item>
        </list>
        <p>Bezlotoxumab, a recently approved human monoclonal antibody targeting <italic toggle="yes">C difficile</italic> toxin, has shown promising results in managing recurrent infections. Clinical studies have demonstrated its efficacy and revealed positive outcomes.<xref ref-type="bibr" rid="article-19632.r44">[44]</xref>&#x000a0;Fecal transplantation, involving the introduction of fecal matter from a healthy donor into the patient's gastrointestinal tract, has reported an 80% to 90% success rate in reducing <italic toggle="yes">C difficile</italic> recurrence.<xref ref-type="bibr" rid="article-19632.r45">[45]</xref></p>
        <p>
<bold>Initial Treatment for&#x000a0;<italic toggle="yes">C difficile</italic>&#x000a0;Infections</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>If fidaxomicin is available, it should be administered 200 mg PO bid for 10 days&#x000a0;instead of vancomycin to treat patients initially.</p>
          </list-item>
          <list-item>
            <p>If fidaxomicin is unavailable, oral vancomycin should be given at 125 mg every 6 hours for 10 days.<xref ref-type="bibr" rid="article-19632.r41">[41]</xref><xref ref-type="bibr" rid="article-19632.r46">[46]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>If neither fidaxomicin&#x000a0;nor vancomycin are available, metronidazole should be administered orally.<xref ref-type="bibr" rid="article-19632.r41">[41]</xref><xref ref-type="bibr" rid="article-19632.r46">[46]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommends fidaxomicin&#x000a0;for subsequent episodes if not administered during the initial episode. If fidaxomicin was previously used, it can be administered again with bezlotoxumab. Bezlotuxumab should be incorporated into oral&#x000a0;SoC treatment for <italic toggle="yes">C difficile</italic> infections with an elevated risk of recurrence when fidaxomicin is inaccessible.<xref ref-type="bibr" rid="article-19632.r41">[41]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Recommendations and Options for Recurrent <italic toggle="yes">C difficile</italic>&#x000a0;Infections</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>For patients with recurrent <italic toggle="yes">C difficile</italic> infections, fidaxomicin is the preferred treatment option in a standard or extended-pulsed regimen, if available, as ESCMID recommends.<xref ref-type="bibr" rid="article-19632.r41">[41]</xref><xref ref-type="bibr" rid="article-19632.r46">[46]</xref></p>
          </list-item>
          <list-item>
            <p>In cases where fidaxomicin is unavailable, vancomycin is an alternative treatment for recurrent <italic toggle="yes">C difficile</italic> infections. This drug can be administered in a tapered and pulsed regimen or a standard course, with doses of oral vancomycin 125 mg every 6 hours for 10 to 14 days, followed by 125 mg every 12 hours for 7 days, then once daily for 7 days, and finally once every 2 to 3 days for 2 to 8 weeks. Alternatively, fidaxomicin 200 mg every 12 hours for 10 days can be considered if vancomycin was used for the initial episode.<xref ref-type="bibr" rid="article-19632.r46">[46]</xref></p>
          </list-item>
          <list-item>
            <p>According to the Infectious Diseases Society of America (IDSA), if recurrence occurs within 6 months of the initial infection, bezlotoxumab should be administered as a co-intervention with&#x000a0;SoC antibiotics (fidaxomicin or vancomycin).<xref ref-type="bibr" rid="article-19632.r46">[46]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>ESCMID recommends using bezlotoxumab along with SoC for the initial, recurrent episode of <italic toggle="yes">C difficile</italic>&#x000a0;infections.<xref ref-type="bibr" rid="article-19632.r41">[41]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Second Subsequent Recurrence of&#x000a0;<italic toggle="yes">C difficile</italic>&#x000a0;Infections</bold>
</p>
        <p>Treatment options for a second or subsequent recurrence of <italic toggle="yes">C difficile</italic> infections include a taper and pulsed vancomycin regimen. This involves oral vancomycin 125 mg every 6 hours for 10 to 14 days, rifaximin 400 mg orally 3 times daily for 20 days, fidaxomicin 200 mg twice daily for 10 days, or fecal transplantation.<xref ref-type="bibr" rid="article-19632.r41">[41]</xref><xref ref-type="bibr" rid="article-19632.r46">[46]</xref></p>
        <p>
<bold>Initial Severe Infections</bold>
</p>
        <p>For an initial fulminant episode with hypotension, shock, ileus, or megacolon, the treatment options include:<xref ref-type="bibr" rid="article-19632.r41">[41]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Oral fidaxomicin&#x000a0;200 mg PO bid or oral vancomycin 500 mg&#x000a0;every 6 hours orally or via a nasogastric tube if ileus is present. In addition, rectal vancomycin enema (500 mg in 100 ml&#x000a0;normal saline per rectum every 6 hours) can be administered.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Additionally, adjunctive therapy with intravenous metronidazole 500 mg every 8 hours is recommended.</p>
          </list-item>
          <list-item>
            <p>Surgical intervention, such as subtotal colectomy with preservation of the rectum, may be necessary for patients with fulminant colitis, particularly those at risk of complications such as toxic megacolon, intestinal perforation, and necrotizing colitis.<xref ref-type="bibr" rid="article-19632.r47">[47]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19632.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnoses for <italic toggle="yes">C difficile</italic> infections include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Crohn disease, diverticulitis, irritable bowel syndrome, malabsorption, peritonitis, <italic toggle="yes">Salmonella</italic> infections, shigellosis, ulcerative colitis, vibrio infections, and viral gastroenteritis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19632.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p><italic toggle="yes">C difficile </italic>infections cause a significant burden on healthcare systems, leading to prolonged hospital stays, escalated healthcare expenses, elevated morbidity and mortality rates, recurrence of the disease, and increased disability-adjusted life years (DALYs). DALYs, a composite health metric, estimate the years lived with disabilities (YLDs)&#x000a0;following&#x000a0;disease onset and years of life lost due to premature mortality (YLLs) compared to a standardized life expectancy.<xref ref-type="bibr" rid="article-19632.r1">[1]</xref><xref ref-type="bibr" rid="article-19632.r22">[22]</xref><xref ref-type="bibr" rid="article-19632.r48">[48]</xref><xref ref-type="bibr" rid="article-19632.r49">[49]</xref><xref ref-type="bibr" rid="article-19632.r50">[50]</xref><xref ref-type="bibr" rid="article-19632.r51">[51]</xref></p>
      </sec>
      <sec id="article-19632.s11" sec-type="Complications">
        <title>Complications</title>
        <p><italic toggle="yes">C difficile</italic> infection continues to be a significant cause of morbidity and mortality among hospitalized patients, with severe cases potentially resulting in toxic megacolon, colonic perforation, and sepsis. The infection is associated with heightened morbidity, mortality, prolonged hospitalization, and increased recurrence rates. In cases of fulminant colitis, surgical intervention such as subtotal colectomy with rectal preservation may be necessary, posing risks of complications such as toxic megacolon, intestinal perforation, and necrotizing colitis.<xref ref-type="bibr" rid="article-19632.r1">[1]</xref><xref ref-type="bibr" rid="article-19632.r22">[22]</xref><xref ref-type="bibr" rid="article-19632.r48">[48]</xref><xref ref-type="bibr" rid="article-19632.r49">[49]</xref><xref ref-type="bibr" rid="article-19632.r50">[50]</xref><xref ref-type="bibr" rid="article-19632.r51">[51]</xref></p>
      </sec>
      <sec id="article-19632.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>When patients are suspected or confirmed to have <italic toggle="yes">C difficile</italic> infection, consultation with various medical specialists may be necessary, particularly in recurrence or severe illness. Primary care and emergency physicians often serve as these patients' initial point of contact. Maintaining a high index of suspicion is crucial for considering <italic toggle="yes">C difficile</italic> in the differential diagnosis of diarrhea, especially in individuals with recent healthcare facility exposure, antibiotic use, or a history of <italic toggle="yes">C difficile</italic> infection. Accurate stool testing is essential for diagnosing <italic toggle="yes">C difficile</italic> infection, and prompt treatment per guidelines is imperative. Infectious disease specialists may be consulted to aid in diagnosis and management, facilitating communication with the microbiology laboratory, particularly in cases of recurrent or severe infections.</p>
        <p>Additionally, clinical pharmacists may offer valuable guidance in treating <italic toggle="yes">C difficile</italic> infections. In cases of severe diarrhea with systemic symptoms such as dehydration, septic shock, acute colitis, or unresponsive toxic megacolon despite medical therapy, consultation with gastroenterologists, intensive care physicians, and surgeons may be necessary. Such patients may require admission to the intensive care unit, and, in severe instances, emergency colectomy may be warranted.&#x000a0;These specialists work collaboratively to provide comprehensive care for patients with <italic toggle="yes">C difficile</italic> diarrhea, addressing various aspects of the infection, its treatment, and associated complications.</p>
      </sec>
      <sec id="article-19632.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should receive comprehensive education regarding the course and treatment of <italic toggle="yes">C difficile</italic> infection, potential recurrence, the judicious use of antibiotics, and preventive measures to contain its spread within households. Adhering to the prescribed treatment duration and abstaining from other antibiotics during <italic toggle="yes">C difficile</italic> treatment&#x000a0;is crucial. Patients must understand that symptoms should gradually resolve and prompt reporting to their clinician is warranted if symptoms persist, worsen, or reappear, as this may indicate recurrence or exacerbation of the original episode. Additionally, patients should be instructed to wash their hands thoroughly with soap and water, as hand antiseptics may not effectively eliminate <italic toggle="yes">C difficile</italic> spores. This practice is especially vital after using the bathroom to mitigate the transmission of <italic toggle="yes">C difficile</italic> within their household.</p>
      </sec>
      <sec id="article-19632.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>
<bold>Prevention&#x000a0;of&#x000a0;<italic toggle="yes">C difficile</italic>&#x000a0;infections</bold>
</p>
        <p>Effective prevention of <italic toggle="yes">C difficile</italic>&#x000a0;infections includes various generalized and specific targeted strategies. Generalized approaches involve early disease detection, isolating patients with dedicated facilities and using contact precautions, and promoting hygiene practices such as thorough handwashing with soap and water. Additionally, comprehensive environmental cleaning, including terminal room cleaning, is crucial. These infection control measures should be applied in both healthcare and community settings. Moreover, prudent antibiotic use and the adoption of antibiotic stewardship programs play a pivotal role in preventing the onset and dissemination of <italic toggle="yes">C difficile</italic> infections within healthcare systems.<xref ref-type="bibr" rid="article-19632.r52">[52]</xref></p>
        <p>
<bold>Ongoing Research</bold>
</p>
        <p>Current research efforts are exploring newer antibiotics, microbiome restoration therapies, and vaccine development for treating and preventing&#x000a0;<italic toggle="yes">C difficile</italic> infections. Ridinilazole, granted Fast Track Status and designated as a Qualified Infectious Disease Product by the U.S. Food and Drug Administration (FDA), holds promise as a potential treatment option.<xref ref-type="bibr" rid="article-19632.r53">[53]</xref> Ribaxamase,&#x000a0;an oral beta-lactamase, is under investigation for its ability to preserve gut bacteria and prevent <italic toggle="yes">C difficile</italic> infections and antibiotic-associated diarrhea. Furthermore, microbiome-based therapies are being studied as an alternative approach to preventing antibiotic-associated diarrhea.<xref ref-type="bibr" rid="article-19632.r54">[54]</xref> Pharmaceutical companies are also actively developing a vaccine to prevent <italic toggle="yes">C difficile</italic>&#x000a0;infections.<xref ref-type="bibr" rid="article-19632.r55">[55]</xref></p>
      </sec>
      <sec id="article-19632.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Treating <italic toggle="yes">C difficile</italic> infections necessitates collaboration among all interprofessional healthcare team members, including infectious disease physicians, clinical pharmacists, microbiologists, gastroenterologists, intensivists, and surgeons. This collaborative approach ensures efficient, comprehensive, and coordinated care, enhancing outcomes for patients with <italic toggle="yes">C difficile</italic> infections. Hand hygiene should be conducted using soap and water rather than alcohol-based products when caring for patients with <italic toggle="yes">C difficile</italic> infection due to the superior efficacy of soap and water in spore removal. To prevent <italic toggle="yes">C difficile</italic> infections, adhere to infection control recommendations and practice judicious antibiotic use. In addition, it is advisable to maintain contact precautions for a minimum of 2 days after diarrhea resolution and to continue such precautions until discharge if infection rates persist despite standard infection control measures.</p>
      </sec>
      <sec id="article-19632.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19632&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19632">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/gut-health/clostridioides-difficile-infection-c-diff/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=19632">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19632/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19632">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-19632.s17">
        <fig id="article-19632.image.f1" position="float" orientation="portrait">
          <caption>
            <p><italic toggle="yes">Clostridioides difficile</italic> Pathology and Diagnosis. Pathological illustration featuring <italic toggle="yes">C difficile</italic> bacteria cultured on blood agar and cycloserine mannitol agar plates after 48 hours. These anaerobic gram-positive rods are associated with antibiotic-associated diarrhea. Contributed by G Jones, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PHIL_3211_lores" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-19632.s18">
        <fig id="article-19632.image.f2" position="float" orientation="portrait">
          <caption>
            <p><italic toggle="yes">Clostridioides difficile</italic> Cultures on Cycloserine Mannitol Agar. The image shows <italic toggle="yes">C difficile</italic> bacteria cultured on cycloserine mannitol agar plates, highlighting its association with antibiotic-associated diarrhea. Contributed by G Jones, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PHIL_3649_lores" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-19632.s19">
        <fig id="article-19632.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Impression Smear of <italic toggle="yes">Clostridioides difficile.</italic> Photomicrograph displays the impression smear of <italic toggle="yes">C difficile</italic> bacteria on cycloserine mannitol blood agar, highlighting pathological features. Contributed by G Jones, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PHIL_3650_lores" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-19632.s20">
        <fig id="article-19632.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Micrograph of <italic toggle="yes">Clostridioides difficile</italic> Showing Colitis. Pathological micrograph displays gram-positive <italic toggle="yes">C difficile</italic> bacteria, indicating colitis infection. Contributed by LS Wiggs&#x000a0;and J Carr; Centers for Disease Control and Prevention</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="6259_lores" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-19632.s21">
        <fig id="article-19632.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Course of <italic toggle="yes">Clostridioides difficile</italic> Infections Illustrated by K Humphreys</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Clostridioides__difficile__Infections" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-19632.s22">
        <title>References</title>
        <ref id="article-19632.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guh</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Mu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Winston</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Farley</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Holzbauer</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Phipps</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Dumyati</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Beldavs</surname>
                <given-names>ZG</given-names>
              </name>
              <name>
                <surname>Kainer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Karlsson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gerding</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>LC</given-names>
              </name>
              <collab>Emerging Infections Program Clostridioides difficile Infection Working Group</collab>
            </person-group>
            <article-title>Trends in U.S. Burden of <italic>Clostridioides difficile</italic> Infection and Outcomes.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Apr</month>
            <day>02</day>
            <volume>382</volume>
            <issue>14</issue>
            <fpage>1320</fpage>
            <page-range>1320-1330</page-range>
            <pub-id pub-id-type="pmid">32242357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>See</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Beldavs</surname>
                <given-names>ZG</given-names>
              </name>
              <name>
                <surname>Winston</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Dumyati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Holzbauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Farley</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Phipps</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Perlmutter</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gerding</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Lessa</surname>
                <given-names>FC</given-names>
              </name>
            </person-group>
            <article-title>NAP1 strain type predicts outcomes from Clostridium difficile infection.</article-title>
            <source>Clin Infect Dis</source>
            <year>2014</year>
            <month>May</month>
            <volume>58</volume>
            <issue>10</issue>
            <fpage>1394</fpage>
            <page-range>1394-400</page-range>
            <pub-id pub-id-type="pmid">24604900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDonald</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Killgore</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Kazakova</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Sambol</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gerding</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>An epidemic, toxin gene-variant strain of Clostridium difficile.</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <month>Dec</month>
            <day>08</day>
            <volume>353</volume>
            <issue>23</issue>
            <fpage>2433</fpage>
            <page-range>2433-41</page-range>
            <pub-id pub-id-type="pmid">16322603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carling</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Parry</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Olmstead</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Environmental approaches to controlling Clostridioides difficile infection in healthcare settings.</article-title>
            <source>Antimicrob Resist Infect Control</source>
            <year>2023</year>
            <month>Sep</month>
            <day>07</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>94</fpage>
            <pub-id pub-id-type="pmid">37679758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gorbach</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>John G. Bartlett: Contributions to the discovery of Clostridium difficile antibiotic-associated diarrhea.</article-title>
            <source>Clin Infect Dis</source>
            <year>2014</year>
            <month>Sep</month>
            <day>15</day>
            <volume>59 Suppl 2</volume>
            <fpage>S66</fpage>
            <page-range>S66-70</page-range>
            <pub-id pub-id-type="pmid">25151480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bartlett</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Gurwith</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gorbach</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Onderdonk</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.</article-title>
            <source>N Engl J Med</source>
            <year>1978</year>
            <month>Mar</month>
            <day>09</day>
            <volume>298</volume>
            <issue>10</issue>
            <fpage>531</fpage>
            <page-range>531-4</page-range>
            <pub-id pub-id-type="pmid">625309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khanafer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vanhems</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barbut</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Luxemburger</surname>
                <given-names>C</given-names>
              </name>
              <collab>CDI01 Study group</collab>
              <name>
                <surname>Demont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hulin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dauwalder</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vandenesch</surname>
                <given-names>F</given-names>
              </name>
              <collab>Teams of:</collab>
              <name>
                <surname>Argaud</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Badet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Barth</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Bertrand</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burillon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chapurlat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chuzeville</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Comte</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Disant</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fessy</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Gouillat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Juillard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lermusiaux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Monneuse</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Morelon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ninet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ponchon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Poulet</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rimmele</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tazarourte</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Factors associated with Clostridium difficile infection: A nested case-control study in a three year prospective cohort.</article-title>
            <source>Anaerobe</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>44</volume>
            <fpage>117</fpage>
            <page-range>117-123</page-range>
            <pub-id pub-id-type="pmid">28279859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eeuwijk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yarzabal</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Robert-Du Ry van Beest Holle</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A Systematic Literature Review on Risk Factors for and Timing of Clostridioides difficile Infection in the United States.</article-title>
            <source>Infect Dis Ther</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>273</fpage>
            <page-range>273-298</page-range>
            <pub-id pub-id-type="pmid">38349594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>TV</given-names>
              </name>
            </person-group>
            <article-title>Clostridium difficile and One Health.</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>26</volume>
            <issue>7</issue>
            <fpage>857</fpage>
            <page-range>857-863</page-range>
            <pub-id pub-id-type="pmid">31682985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kyne</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hamel</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Polavaram</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile.</article-title>
            <source>Clin Infect Dis</source>
            <year>2002</year>
            <month>Feb</month>
            <day>01</day>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>346</fpage>
            <page-range>346-53</page-range>
            <pub-id pub-id-type="pmid">11774082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelly</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Allegretti</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Review Article: Gastroenterology and Clostridium difficile Infection: Past, Present, and Future.</article-title>
            <source>Clin Infect Dis</source>
            <year>2023</year>
            <month>Dec</month>
            <day>05</day>
            <volume>77</volume>
            <issue>Suppl 6</issue>
            <fpage>S463</fpage>
            <page-range>S463-S470</page-range>
            <pub-id pub-id-type="pmid">38051967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuehne</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Cartman</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Heap</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Cockayne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Minton</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>The role of toxin A and toxin B in Clostridium difficile infection.</article-title>
            <source>Nature</source>
            <year>2010</year>
            <month>Oct</month>
            <day>07</day>
            <volume>467</volume>
            <issue>7316</issue>
            <fpage>711</fpage>
            <page-range>711-3</page-range>
            <pub-id pub-id-type="pmid">20844489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghose</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clostridium difficile infection in the twenty-first century.</article-title>
            <source>Emerg Microbes Infect</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>2</volume>
            <issue>9</issue>
            <fpage>e62</fpage>
            <pub-id pub-id-type="pmid">26038491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouza</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Alonso</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Clinical manifestations, treatment and control of infections caused by Clostridium difficile.</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>11 Suppl 4</volume>
            <fpage>57</fpage>
            <page-range>57-64</page-range>
            <pub-id pub-id-type="pmid">15997485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lessa</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Winston</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>LC</given-names>
              </name>
              <collab>Emerging Infections Program C. difficile Surveillance Team</collab>
            </person-group>
            <article-title>Burden of Clostridium difficile infection in the United States.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Jun</month>
            <day>11</day>
            <volume>372</volume>
            <issue>24</issue>
            <fpage>2369</fpage>
            <page-range>2369-70</page-range>
            <pub-id pub-id-type="pmid">26061850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khanna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baddour</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Huskins</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Kammer</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Faubion</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Zinsmeister</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Harmsen</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Pardi</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology of Clostridium difficile infection in children: a population-based study.</article-title>
            <source>Clin Infect Dis</source>
            <year>2013</year>
            <month>May</month>
            <volume>56</volume>
            <issue>10</issue>
            <fpage>1401</fpage>
            <page-range>1401-6</page-range>
            <pub-id pub-id-type="pmid">23408679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davey</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fenelon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Finch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gould</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ramsay</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wiffen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of antimicrobial drug prescribing in hospitals.</article-title>
            <source>Emerg Infect Dis</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>211</fpage>
            <page-range>211-6</page-range>
            <pub-id pub-id-type="pmid">16494744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Dorp</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Notermans</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Alblas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gastmeier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mentula</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nagy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Spigaglia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ivanova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fitzpatrick</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barbut</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Kinross</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Suetens</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kuijper</surname>
                <given-names>EJ</given-names>
              </name>
              <collab>European Clostridium difficile Infection Surveillance Network (ECDIS-Net) project on behalf of all participants</collab>
            </person-group>
            <article-title>Survey of diagnostic and typing capacity for Clostridium difficile infection in Europe, 2011 and 2014.</article-title>
            <source>Euro Surveill</source>
            <year>2016</year>
            <month>Jul</month>
            <day>21</day>
            <volume>21</volume>
            <issue>29</issue>
            <pub-id pub-id-type="pmid">27469624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giancola</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Gentry</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of the Clostridium difficile BI/NAP1/027 strain across the United States Veterans Health Administration.</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>24</volume>
            <issue>8</issue>
            <fpage>877</fpage>
            <page-range>877-881</page-range>
            <pub-id pub-id-type="pmid">29174729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hall</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Curns</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Parashar</surname>
                <given-names>UD</given-names>
              </name>
              <name>
                <surname>Lopman</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007.</article-title>
            <source>Clin Infect Dis</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>55</volume>
            <issue>2</issue>
            <fpage>216</fpage>
            <page-range>216-23</page-range>
            <pub-id pub-id-type="pmid">22491338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dubberke</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Burden of Clostridium difficile on the healthcare system.</article-title>
            <source>Clin Infect Dis</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>55 Suppl 2</volume>
            <issue>Suppl 2</issue>
            <fpage>S88</fpage>
            <page-range>S88-92</page-range>
            <pub-id pub-id-type="pmid">22752870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lessa</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Mu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bamberg</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Beldavs</surname>
                <given-names>ZG</given-names>
              </name>
              <name>
                <surname>Dumyati</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Farley</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Holzbauer</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Meek</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Phipps</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Winston</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Limbago</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Fridkin</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Gerding</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>Burden of Clostridium difficile infection in the United States.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Feb</month>
            <day>26</day>
            <volume>372</volume>
            <issue>9</issue>
            <fpage>825</fpage>
            <page-range>825-34</page-range>
            <pub-id pub-id-type="pmid">25714160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gentry</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Continued decline in the prevalence of the Clostridioides difficile BI/NAP1/027 strain across the United States Veterans Health Administration.</article-title>
            <source>Diagn Microbiol Infect Dis</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>100</volume>
            <issue>2</issue>
            <fpage>115308</fpage>
            <pub-id pub-id-type="pmid">33626478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dingle</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Didelot</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Quan</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Eyre</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Stoesser</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Golubchik</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vaughan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Finney</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Wyllie</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Oakley</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Fawley</surname>
                <given-names>WN</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gorbach</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>EJC</given-names>
              </name>
              <name>
                <surname>Citron</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hope</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>TEA</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Crook</surname>
                <given-names>DW</given-names>
              </name>
              <collab>Modernising Medical Microbiology Informatics Group</collab>
            </person-group>
            <article-title>Effects of control interventions on Clostridium difficile infection in England: an observational study.</article-title>
            <source>Lancet Infect Dis</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>411</fpage>
            <page-range>411-421</page-range>
            <pub-id pub-id-type="pmid">28130063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viprey</surname>
                <given-names>VF</given-names>
              </name>
              <name>
                <surname>Granata</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vendrik</surname>
                <given-names>KEW</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Petrosillo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kuijper</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Vilken</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lammens</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schotsman</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Cataldo</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>van der Kooi</surname>
                <given-names>TII</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>KA</given-names>
              </name>
              <collab>COMBACTE-CDI consortium</collab>
            </person-group>
            <article-title>European survey on the current surveillance practices, management guidelines, treatment pathways and heterogeneity of testing of Clostridioides difficile, 2018-2019: results from The Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI).</article-title>
            <source>J Hosp Infect</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>131</volume>
            <fpage>213</fpage>
            <page-range>213-220</page-range>
            <pub-id pub-id-type="pmid">36462673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>ZX</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Koya</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>ZS</given-names>
              </name>
            </person-group>
            <article-title>Microbiota in health and diseases.</article-title>
            <source>Signal Transduct Target Ther</source>
            <year>2022</year>
            <month>Apr</month>
            <day>23</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>135</fpage>
            <pub-id pub-id-type="pmid">35461318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sehgal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Gut microbiome and <italic>Clostridioides difficile</italic> infection: a closer look at the microscopic interface.</article-title>
            <source>Therap Adv Gastroenterol</source>
            <year>2021</year>
            <volume>14</volume>
            <fpage>1756284821994736</fpage>
            <pub-id pub-id-type="pmid">33747125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jangi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lamont</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life.</article-title>
            <source>J Pediatr Gastroenterol Nutr</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>51</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-7</page-range>
            <pub-id pub-id-type="pmid">20512057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Osaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hanawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kurata</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Okazaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Manzoku</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taguchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Inamatsu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kamiya</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Molecular and microbiological characterization of Clostridium difficile isolates from single, relapse, and reinfection cases.</article-title>
            <source>J Clin Microbiol</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>915</fpage>
            <page-range>915-21</page-range>
            <pub-id pub-id-type="pmid">22205786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dove</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Phelps</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Lyerly</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Wilkins</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Molecular characterization of the Clostridium difficile toxin A gene.</article-title>
            <source>Infect Immun</source>
            <year>1990</year>
            <month>Feb</month>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>480</fpage>
            <page-range>480-8</page-range>
            <pub-id pub-id-type="pmid">2105276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Just</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Selzer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wilm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>von Eichel-Streiber</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aktories</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Glucosylation of Rho proteins by Clostridium difficile toxin B.</article-title>
            <source>Nature</source>
            <year>1995</year>
            <month>Jun</month>
            <day>08</day>
            <volume>375</volume>
            <issue>6531</issue>
            <fpage>500</fpage>
            <page-range>500-3</page-range>
            <pub-id pub-id-type="pmid">7777059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Souza</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Melo-Filho</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Rocha</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Lyerly</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Cunha</surname>
                <given-names>FQ</given-names>
              </name>
              <name>
                <surname>Lima</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ribeiro</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>The involvement of macrophage-derived tumour necrosis factor and lipoxygenase products on the neutrophil recruitment induced by Clostridium difficile toxin B.</article-title>
            <source>Immunology</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>91</volume>
            <issue>2</issue>
            <fpage>281</fpage>
            <page-range>281-8</page-range>
            <pub-id pub-id-type="pmid">9227329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bagdasarian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Malani</surname>
                <given-names>PN</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of Clostridium difficile in adults: a systematic review.</article-title>
            <source>JAMA</source>
            <year>2015</year>
            <month>Jan</month>
            <day>27</day>
            <volume>313</volume>
            <issue>4</issue>
            <fpage>398</fpage>
            <page-range>398-408</page-range>
            <pub-id pub-id-type="pmid">25626036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubin</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Bodenstein</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Kent</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <article-title>Severe Clostridium difficile colitis.</article-title>
            <source>Dis Colon Rectum</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>350</fpage>
            <page-range>350-4</page-range>
            <pub-id pub-id-type="pmid">7720439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rybolt</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Laughon</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Greenough</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Protein-losing enteropathy associated with Clostridium difficile infection.</article-title>
            <source>Lancet</source>
            <year>1989</year>
            <month>Jun</month>
            <day>17</day>
            <volume>1</volume>
            <issue>8651</issue>
            <fpage>1353</fpage>
            <page-range>1353-5</page-range>
            <pub-id pub-id-type="pmid">2567373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mattila</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Arkkila</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mattila</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Tarkka</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tissari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Anttila</surname>
                <given-names>VJ</given-names>
              </name>
            </person-group>
            <article-title>Extraintestinal Clostridium difficile infections.</article-title>
            <source>Clin Infect Dis</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>e148</fpage>
            <page-range>e148-53</page-range>
            <pub-id pub-id-type="pmid">23771984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fekety</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McFarland</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Surawicz</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Elmer</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Mulligan</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial.</article-title>
            <source>Clin Infect Dis</source>
            <year>1997</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>324</fpage>
            <page-range>324-33</page-range>
            <pub-id pub-id-type="pmid">9114180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDonald</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Gerding</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bakken</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Coffin</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Dubberke</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Garey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Gould</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Loo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Shaklee Sammons</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sandora</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).</article-title>
            <source>Clin Infect Dis</source>
            <year>2018</year>
            <month>Mar</month>
            <day>19</day>
            <volume>66</volume>
            <issue>7</issue>
            <fpage>e1</fpage>
            <page-range>e1-e48</page-range>
            <pub-id pub-id-type="pmid">29462280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Gerding</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Loo</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Pepin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>MH</given-names>
              </name>
              <collab>Society for Healthcare Epidemiology of America</collab>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).</article-title>
            <source>Infect Control Hosp Epidemiol</source>
            <year>2010</year>
            <month>May</month>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>431</fpage>
            <page-range>431-55</page-range>
            <pub-id pub-id-type="pmid">20307191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crobach</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Planche</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eckert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barbut</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Terveer</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Dekkers</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Kuijper</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection.</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>22 Suppl 4</volume>
            <fpage>S63</fpage>
            <page-range>S63-81</page-range>
            <pub-id pub-id-type="pmid">27460910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Prehn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reigadas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vogelzang</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Bouza</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hristea</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guery</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Krutova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nor&#x000e9;n</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Allerberger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Coia</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Goorhuis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Rossen</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Ooijevaar</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Scharvik Olesen</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Tschudin-Sutter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Vehreschild</surname>
                <given-names>MJGT</given-names>
              </name>
              <name>
                <surname>Fitzpatrick</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kuijper</surname>
                <given-names>EJ</given-names>
              </name>
              <collab>Guideline Committee of the European Study Group on Clostridioides difficile</collab>
            </person-group>
            <article-title>European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>27 Suppl 2</volume>
            <fpage>S1</fpage>
            <page-range>S1-S21</page-range>
            <pub-id pub-id-type="pmid">34678515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelly</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Allegretti</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>LaPlante</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Limketkai</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Stollman</surname>
                <given-names>NH</given-names>
              </name>
            </person-group>
            <article-title>ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2021</year>
            <month>Jun</month>
            <day>01</day>
            <volume>116</volume>
            <issue>6</issue>
            <fpage>1124</fpage>
            <page-range>1124-1147</page-range>
            <pub-id pub-id-type="pmid">34003176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bishop</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Tiruvoipati</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2022</year>
            <month>Dec</month>
            <day>23</day>
            <volume>78</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-30</page-range>
            <pub-id pub-id-type="pmid">36441203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bartlett</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Bezlotoxumab - A New Agent for Clostridium difficile Infection.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Jan</month>
            <day>26</day>
            <volume>376</volume>
            <issue>4</issue>
            <fpage>381</fpage>
            <page-range>381-382</page-range>
            <pub-id pub-id-type="pmid">28121509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kassam</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Review of the emerging treatment of Clostridium difficile infection with fecal microbiota transplantation and insights into future challenges.</article-title>
            <source>Clin Lab Med</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>787</fpage>
            <page-range>787-98</page-range>
            <pub-id pub-id-type="pmid">25439277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lavergne</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Skinner</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gonzales-Luna</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Garey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults.</article-title>
            <source>Clin Infect Dis</source>
            <year>2021</year>
            <month>Sep</month>
            <day>07</day>
            <volume>73</volume>
            <issue>5</issue>
            <fpage>e1029</fpage>
            <page-range>e1029-e1044</page-range>
            <pub-id pub-id-type="pmid">34164674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steele</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>McCormick</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Melton</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Paquette</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rivadeneira</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Buie</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Rafferty</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Practice parameters for the management of Clostridium difficile infection.</article-title>
            <source>Dis Colon Rectum</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-24</page-range>
            <pub-id pub-id-type="pmid">25489690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marra</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Perencevich</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Samore</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khader</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Chorazy</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Herwaldt</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Diekema</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kuxhausen</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Blevins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>McDanel</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Balkenende</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schweizer</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Incidence and Outcomes Associated With Clostridium difficile Infections: A Systematic Review and Meta-analysis.</article-title>
            <source>JAMA Netw Open</source>
            <year>2020</year>
            <month>Jan</month>
            <day>03</day>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>e1917597</fpage>
            <pub-id pub-id-type="pmid">31913488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cassini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Plachouras</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Eckmanns</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Abu Sin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blank</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Ducomble</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Haller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harder</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Klingeberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sixtensson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Velasco</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wei&#x000df;</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kramarz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Monnet</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Kretzschmar</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Suetens</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Burden of Six Healthcare-Associated Infections on European Population Health: Estimating Incidence-Based Disability-Adjusted Life Years through a Population Prevalence-Based Modelling Study.</article-title>
            <source>PLoS Med</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>10</issue>
            <fpage>e1002150</fpage>
            <pub-id pub-id-type="pmid">27755545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Magill</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bamberg</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Beldavs</surname>
                <given-names>ZG</given-names>
              </name>
              <name>
                <surname>Dumyati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kainer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lynfield</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maloney</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McAllister-Hollod</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nadle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Fridkin</surname>
                <given-names>SK</given-names>
              </name>
              <collab>Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team</collab>
            </person-group>
            <article-title>Multistate point-prevalence survey of health care-associated infections.</article-title>
            <source>N Engl J Med</source>
            <year>2014</year>
            <month>Mar</month>
            <day>27</day>
            <volume>370</volume>
            <issue>13</issue>
            <fpage>1198</fpage>
            <page-range>1198-208</page-range>
            <pub-id pub-id-type="pmid">24670166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cioni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Viale</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Frasson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cipollini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Menichetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Petrosillo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brunati</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spigaglia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vismara</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bielli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barbanti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Landini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Panigada</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gussoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bonizzoni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gesu</surname>
                <given-names>GP</given-names>
              </name>
              <collab>Research Department of FADOI</collab>
            </person-group>
            <article-title>Epidemiology and outcome of&#x000a0;Clostridium difficile&#x000a0;infections in patients hospitalized in Internal Medicine:&#x000a0;findings from the nationwide FADOI-PRACTICE study.</article-title>
            <source>BMC Infect Dis</source>
            <year>2016</year>
            <month>Nov</month>
            <day>08</day>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>656</fpage>
            <pub-id pub-id-type="pmid">27825317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kociolek</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Gerding</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Carrico</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carling</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Donskey</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Dumyati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kuhar</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Loo</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Maragakis</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Pogorzelska-Maziarz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sandora</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Yokoe</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dubberke</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Strategies to prevent <italic>Clostridioides difficile</italic> infections in acute-care hospitals: 2022 Update.</article-title>
            <source>Infect Control Hosp Epidemiol</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>527</fpage>
            <page-range>527-549</page-range>
            <pub-id pub-id-type="pmid">37042243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonzales-Luna</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Carlson</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Garey</surname>
                <given-names>KW</given-names>
              </name>
            </person-group>
            <article-title>Emerging Options for the Prevention and Management of Clostridioides difficile Infection.</article-title>
            <source>Drugs</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>83</volume>
            <issue>2</issue>
            <fpage>105</fpage>
            <page-range>105-116</page-range>
            <pub-id pub-id-type="pmid">36645620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kokai-Kun</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Trout</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cope</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ajami</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Degar</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Connelly</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ribaxamase, an Orally Administered &#x003b2;-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone.</article-title>
            <source>Infect Drug Resist</source>
            <year>2020</year>
            <volume>13</volume>
            <fpage>2521</fpage>
            <page-range>2521-2535</page-range>
            <pub-id pub-id-type="pmid">32801790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19632.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heuler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chandra</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Mucosal Vaccination Strategies against <italic>Clostridioides difficile</italic> Infection.</article-title>
            <source>Vaccines (Basel)</source>
            <year>2023</year>
            <month>Apr</month>
            <day>23</day>
            <volume>11</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">37242991</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
